Navigation Links
Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer,Patients Treated with Therapy Based on Ratiometric Dosing

Phase I results for CPX-1 presented at ASCO confirm safety findings and demonstrate clinical benefit in more than 70% of patients with colorectal and other types of cancer.

PRINCETON, N.J., June 04, 2007 /PRNewswire/ -- Celator Pharmaceuticals announced positive safety and efficacy results from its Phase I study of CPX-1 (Irinotecan HCI:Floxuridine), Liposome Injection in patients with heavily pre-treated, advanced solid tumors. Results were presented yesterday in a poster presentation at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

Among a total of 33 patients with different types of cancer who were treated in the dose-escalating study, 73% showed clinical benefit including either partial regression or stable disease. In ten patients delay of disease progression was greater than six months. Among a subset of 15 patients with colorectal cancer, median duration of progression-free survival was 5.3 months. Of these patients, 80% received CPX-1 as a third, fourth or fifth line treatment, and 66% had prior treatment with irinotecan.

"These results provide us with the essential dosing and safety data we need to advance CPX-1 through Phase 2 clinical trials and toward commercialization. Even more importantly, this study also produced very encouraging results related to clinical benefit, which is uncommon in a Phase 1 study," said Andrew Janoff, Ph.D., CEO of Celator.

CPX-1 is a combination therapy including irinotecan HCI and floxuridine, two approved and well known drug agents to treat cancer. The formulation of CPX-1 was developed based on ratiometric dosing using Celator's CombiPlex(TM) technology platform, a proprietary technology that identifies the optimal ratio of drugs to use in combination therapies and then incorporates an advanced nanoparticle delivery system to maintain those optimal ratios when drugs are administered and metabolized in patients. Pending regula tory approval, CPX-1 would be the first commercially-available combination therapy based on Celator's ratiometric dosing drug development platform.

"What we found in this study is that our ratiometric dosing formulation of irinotecan and floxuridine achieved the targeted 1:1 molar ratio that provided synergistic benefits to all patients including those who had been treated previously with irinotecan. Based on these findings, Celator is moving forward with a Phase 2 study for CPX-1 that includes treatment of irinotecan- naïve patients as well as patients who are resistant or refractory to irinotecan," said Arthur Louie, M.D., Celator's chief medical officer.

The ongoing phase 2 study for CPX-1 involves patients with colorectal cancer who will be treated at sites in the U.S. and Canada. For information, visit: www.clinicaltrials.gov/ct/show/NCT00361842?order=1.

ABOUT CELATOR

Celator Pharmaceuticals, Inc., formerly Celator Technologies, Inc., is a privately held biopharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex, the company's drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies based on the optimal ratio of drug agents to target cancer cells effectively. The company pipeline includes: CPX-1, currently in Phase 2 trials as a treatment option for colorectal cancer; CPX-351, currently in Phase 1 trials as a treatment for leukemia (for information visit www.clinicaltrials.gov/ct/show/NCT00389428?order=2); CPX 571, now positioned to advance to Phase 1 trials and targeting small cell lung cancer; and multiple early stage pre-clinical development programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents.

CONTACT: Paul Hendley of Celator Pharmaceuticals, +1-212-253-8881, phendley@berrypr.com

Web site: http://www.clinicaltrials.gov/ct/show/NCT00361842?order=1/http://www.clinicaltrials.gov/ct/show/NCT00389428?order=2//

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ROCHESTER, N.Y. , March 22, 2017 /PRNewswire/ ... Steriliz R-D™ Rapid Disinfector™ is the proven ultraviolet-C ... that cause healthcare-associated infections (HAIs). ... American Journal of Infection Control , the peer-reviewed ... testing and experiences of Vancouver General Hospital and ...
(Date:3/22/2017)... 22, 2017 FinancialBuzz.com News Commentary ... rapidly due to the significant development and innovation in ... Market Research, the global electrophysiology market was worth $3.42 ... billion by 2022, with a GAGR of 13.4%. Electrophysiology ... diagnose abnormal heartbeats or arrhythmia. The report indicates that ...
(Date:3/22/2017)... , March 22, 2017 Kalorama Information has ... important to those following the industry.  This month the FDA ... test, and the POC testing market has reached $18.4 ... subsidiary is facing a legal battle and the acquisition ... Coulter launched a new chemistry analyzer and researchers ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... ... publication of “Profiling protein expression in circulating tumor cells using microfluidic western blotting” ... use of the Vortex technology to capture CTCs and a microfluidic ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... Milpitas with a robust, ongoing community enrichment program, has announced their latest charity ... which has provided for the critical needs of homeless families with children for ...
(Date:3/22/2017)... ... March 22, 2017 , ... In recognition of Colon ... enterprise focused on cancer patients, cancer centers and advocacy groups, and MJH Studios™, ... video series, “No Ifs, Ands, or Butts,” that focuses on Colorectal Cancer detection, ...
(Date:3/22/2017)... ... March 22, 2017 , ... Drs. Jennifer Houck, Lauren ... base to accept new patients in need of skilled pediatric dentistry in ... Dental Care offers pediatric patients routine treatments, including cavities, sealants and fluoride applications, in ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Carballo Agency, ... and the New York metropolitan region, is embarking on a cooperative charity drive ... , At present, more than two and a half million children in the ...
Breaking Medicine News(10 mins):